Oncology Institute (TOI) Projected to Post Earnings on Thursday

Oncology Institute (NASDAQ:TOI) is expected to be releasing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Oncology Institute to post earnings of ($0.07) per share and revenue of $143.35 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:30 PM ET.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $141.96 million for the quarter, compared to analysts’ expectations of $139.78 million.

Oncology Institute Trading Down 2.5%

Oncology Institute stock opened at $3.98 on Wednesday. Oncology Institute has a 12-month low of $2.02 and a 12-month high of $4.88. The stock has a market cap of $393.38 million, a P/E ratio of -7.11 and a beta of 0.33. The company has a fifty day simple moving average of $3.16 and a 200-day simple moving average of $3.35.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TOI shares. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price target on shares of Oncology Institute in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a report on Monday, April 20th. BTIG Research reiterated a “buy” rating and issued a $7.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Finally, B. Riley Financial increased their price objective on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Insider Buying and Selling at Oncology Institute

In other news, Director Mohit Kaushal sold 38,433 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $3.50, for a total transaction of $134,515.50. Following the completion of the sale, the director directly owned 172,583 shares of the company’s stock, valued at $604,040.50. The trade was a 18.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were acquired at an average cost of $3.10 per share, with a total value of $62,000.00. Following the completion of the transaction, the insider owned 10,499,358 shares in the company, valued at $32,548,009.80. This trade represents a 0.19% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 568,985 shares of company stock valued at $1,759,601 over the last three months. Corporate insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Oncology Institute

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. LPL Financial LLC boosted its position in Oncology Institute by 1.5% in the 4th quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock valued at $964,000 after buying an additional 3,900 shares during the last quarter. AQR Capital Management LLC boosted its position in Oncology Institute by 9.1% in the 4th quarter. AQR Capital Management LLC now owns 48,072 shares of the company’s stock valued at $171,000 after buying an additional 4,007 shares during the last quarter. HighTower Advisors LLC boosted its position in Oncology Institute by 5.5% in the 4th quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock valued at $306,000 after buying an additional 4,489 shares during the last quarter. Cetera Investment Advisers boosted its position in Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after buying an additional 4,545 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Oncology Institute by 141.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock valued at $42,000 after buying an additional 7,091 shares during the last quarter. 36.86% of the stock is owned by hedge funds and other institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.